Identification of serum metabolic traits of AIWG in first-episode schizophrenia patients
Abstract Background Antipsychotic-induced weight gain (AIWG) is a common side effect of antipsychotic drugs and may lead to cardiometabolic comorbidities. There is an urgent public health need to identify patients at high risk of AIWG and determine potential biomarkers for AIWG. Methods In the Seque...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | BMC Psychiatry |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12888-024-06413-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846100995598188544 |
|---|---|
| author | Suzhen Zhang Zhaolin Zhai Tianhao Gao Xinping Kuai Xuan Li Yuke Dong Chang Lu Kaiming Zhuo Qiong Xiang Dengtang Liu |
| author_facet | Suzhen Zhang Zhaolin Zhai Tianhao Gao Xinping Kuai Xuan Li Yuke Dong Chang Lu Kaiming Zhuo Qiong Xiang Dengtang Liu |
| author_sort | Suzhen Zhang |
| collection | DOAJ |
| description | Abstract Background Antipsychotic-induced weight gain (AIWG) is a common side effect of antipsychotic drugs and may lead to cardiometabolic comorbidities. There is an urgent public health need to identify patients at high risk of AIWG and determine potential biomarkers for AIWG. Methods In the Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) trail, first-episode schizophrenia patients were randomly assigned to olanzapine, risperidone, perphenazine, amisulpride or aripiprazole for 8 weeks. We applied absolute quantitative lipidomics at baseline and after 8 weeks of antipsychotic treatment in 80 patients. To evaluate the effects of AIWG on lipid profile, 25 patients with ≥ 7% weight changes (weight gain, WG) and 28 patients with <|3|% weight changes (weight stable, WS) were investigated, separately. Results We found that baseline CerP(d40:3) and PC(20:1_22:6) were positively associated with weight changes at follow-up (r > 0.4, pFDR < 0.05). Additionally, baseline CerP(d40:3) and PC(20:1_22:6) independently predicted rapid weight gain, with receiver operating curve (ROC) of 0.76 (95% CI: 0.63–0.90), and 0.75 (95% CI: 0.62–0.88), respectively. Compared with baseline, levels of 45 differential lipid metabolites (fold change > 1.2, VIP > 1 and pFDR < 0.05) were significantly higher in the WG group. Interestingly, no differential lipid metabolites were identified in the WS group. The LASSO regression model identified 18 AIWG lipid signatures, including 2 cholesterol esters (ChEs), 1 diglyceride (DG), 12 phosphatidylcholines (PCs), 1 phosphatidylglycerol (PG), 1 phosphatidylinositol (PI), and 1 sphingomyelin (SM), with the ChE(16:1) contributing the most. Furthermore, the level changes of ChE(16:1) were positively associated with weight gain(r = 0.67, pFDR < 0.05). Conclusion Our findings indicate that lipid profile may serve as predictors of rapid weight gain in schizophrenia and provide useful markers for AIWG intervention. |
| format | Article |
| id | doaj-art-af22e4637fc742dfaed7e79e8afd7cab |
| institution | Kabale University |
| issn | 1471-244X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Psychiatry |
| spelling | doaj-art-af22e4637fc742dfaed7e79e8afd7cab2024-12-29T12:40:19ZengBMCBMC Psychiatry1471-244X2024-12-012411910.1186/s12888-024-06413-8Identification of serum metabolic traits of AIWG in first-episode schizophrenia patientsSuzhen Zhang0Zhaolin Zhai1Tianhao Gao2Xinping Kuai3Xuan Li4Yuke Dong5Chang Lu6Kaiming Zhuo7Qiong Xiang8Dengtang Liu9Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of MedicineDivision of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of MedicineDivision of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of MedicineDivision of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of MedicineDivision of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of MedicineDivision of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of MedicineDivision of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of MedicineDivision of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of MedicineDivision of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of MedicineDivision of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of MedicineAbstract Background Antipsychotic-induced weight gain (AIWG) is a common side effect of antipsychotic drugs and may lead to cardiometabolic comorbidities. There is an urgent public health need to identify patients at high risk of AIWG and determine potential biomarkers for AIWG. Methods In the Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) trail, first-episode schizophrenia patients were randomly assigned to olanzapine, risperidone, perphenazine, amisulpride or aripiprazole for 8 weeks. We applied absolute quantitative lipidomics at baseline and after 8 weeks of antipsychotic treatment in 80 patients. To evaluate the effects of AIWG on lipid profile, 25 patients with ≥ 7% weight changes (weight gain, WG) and 28 patients with <|3|% weight changes (weight stable, WS) were investigated, separately. Results We found that baseline CerP(d40:3) and PC(20:1_22:6) were positively associated with weight changes at follow-up (r > 0.4, pFDR < 0.05). Additionally, baseline CerP(d40:3) and PC(20:1_22:6) independently predicted rapid weight gain, with receiver operating curve (ROC) of 0.76 (95% CI: 0.63–0.90), and 0.75 (95% CI: 0.62–0.88), respectively. Compared with baseline, levels of 45 differential lipid metabolites (fold change > 1.2, VIP > 1 and pFDR < 0.05) were significantly higher in the WG group. Interestingly, no differential lipid metabolites were identified in the WS group. The LASSO regression model identified 18 AIWG lipid signatures, including 2 cholesterol esters (ChEs), 1 diglyceride (DG), 12 phosphatidylcholines (PCs), 1 phosphatidylglycerol (PG), 1 phosphatidylinositol (PI), and 1 sphingomyelin (SM), with the ChE(16:1) contributing the most. Furthermore, the level changes of ChE(16:1) were positively associated with weight gain(r = 0.67, pFDR < 0.05). Conclusion Our findings indicate that lipid profile may serve as predictors of rapid weight gain in schizophrenia and provide useful markers for AIWG intervention.https://doi.org/10.1186/s12888-024-06413-8SchizophreniaAntipsychoticWeight gainLipid |
| spellingShingle | Suzhen Zhang Zhaolin Zhai Tianhao Gao Xinping Kuai Xuan Li Yuke Dong Chang Lu Kaiming Zhuo Qiong Xiang Dengtang Liu Identification of serum metabolic traits of AIWG in first-episode schizophrenia patients BMC Psychiatry Schizophrenia Antipsychotic Weight gain Lipid |
| title | Identification of serum metabolic traits of AIWG in first-episode schizophrenia patients |
| title_full | Identification of serum metabolic traits of AIWG in first-episode schizophrenia patients |
| title_fullStr | Identification of serum metabolic traits of AIWG in first-episode schizophrenia patients |
| title_full_unstemmed | Identification of serum metabolic traits of AIWG in first-episode schizophrenia patients |
| title_short | Identification of serum metabolic traits of AIWG in first-episode schizophrenia patients |
| title_sort | identification of serum metabolic traits of aiwg in first episode schizophrenia patients |
| topic | Schizophrenia Antipsychotic Weight gain Lipid |
| url | https://doi.org/10.1186/s12888-024-06413-8 |
| work_keys_str_mv | AT suzhenzhang identificationofserummetabolictraitsofaiwginfirstepisodeschizophreniapatients AT zhaolinzhai identificationofserummetabolictraitsofaiwginfirstepisodeschizophreniapatients AT tianhaogao identificationofserummetabolictraitsofaiwginfirstepisodeschizophreniapatients AT xinpingkuai identificationofserummetabolictraitsofaiwginfirstepisodeschizophreniapatients AT xuanli identificationofserummetabolictraitsofaiwginfirstepisodeschizophreniapatients AT yukedong identificationofserummetabolictraitsofaiwginfirstepisodeschizophreniapatients AT changlu identificationofserummetabolictraitsofaiwginfirstepisodeschizophreniapatients AT kaimingzhuo identificationofserummetabolictraitsofaiwginfirstepisodeschizophreniapatients AT qiongxiang identificationofserummetabolictraitsofaiwginfirstepisodeschizophreniapatients AT dengtangliu identificationofserummetabolictraitsofaiwginfirstepisodeschizophreniapatients |